138 related articles for article (PubMed ID: 19065700)
21. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
[TBL] [Abstract][Full Text] [Related]
22. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2007 Jul; 66(7):921-6. PubMed ID: 17301106
[TBL] [Abstract][Full Text] [Related]
23. [Juvenile rheumatoid arthritis].
Honkanen V; Lahdenne P
Duodecim; 2000; 116(8):839-43. PubMed ID: 11787127
[No Abstract] [Full Text] [Related]
24. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
[No Abstract] [Full Text] [Related]
25. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab.
Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
Scand J Rheumatol; 2011 Mar; 40(2):150-2. PubMed ID: 20868307
[No Abstract] [Full Text] [Related]
26. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
de Vries MK; Wolbink GJ; Stapel SO; de Groot ER; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
[No Abstract] [Full Text] [Related]
27. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
Bendtzen K
Arthritis Rheum; 2011 Apr; 63(4):867-70. PubMed ID: 21452309
[No Abstract] [Full Text] [Related]
28. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
[No Abstract] [Full Text] [Related]
29. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T
Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168
[No Abstract] [Full Text] [Related]
30. Rheumatoid arthritis.
Burchini G; Orsi C
N Engl J Med; 2004 Sep; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
[No Abstract] [Full Text] [Related]
31. Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis.
Park JH; Lee J; Lee JH; Lee DY; Koh EM
Dermatology; 2012; 225(3):259-63. PubMed ID: 23257839
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Scott DL; Kingsley GH
N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
[No Abstract] [Full Text] [Related]
33. Use of adalimumab in poststreptococcal reactive arthritis.
Sánchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N
J Clin Rheumatol; 2007 Jun; 13(3):176. PubMed ID: 17551391
[No Abstract] [Full Text] [Related]
34. [The European Commission approves the use of adalimumab for children ages 4 to 12].
Avit JB
Soins Pediatr Pueric; 2012; (267):10. PubMed ID: 22880320
[No Abstract] [Full Text] [Related]
35. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
[No Abstract] [Full Text] [Related]
36. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
[TBL] [Abstract][Full Text] [Related]
37. Differentiating the efficacy of tumor necrosis factor inhibitors.
Haraoui B
J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
[TBL] [Abstract][Full Text] [Related]
38. New drugs for rheumatoid arthritis.
Messori A; Santarlasci B; Vaiani M
N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436
[No Abstract] [Full Text] [Related]
39. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
Stuhlmüller B; Häupl T; Hernandez MM; Grützkau A; Kuban RJ; Tandon N; Voss JW; Salfeld J; Kinne RW; Burmester GR
Clin Pharmacol Ther; 2010 Mar; 87(3):311-21. PubMed ID: 20032971
[TBL] [Abstract][Full Text] [Related]
40. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]